KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gilead Sciences (GILD) Asset Writedowns and Impairment (2016 - 2025)

Historic Asset Writedowns and Impairment for Gilead Sciences (GILD) over the last 5 years, with Q2 2025 value amounting to $190.0 million.

  • Gilead Sciences' Asset Writedowns and Impairment changed N/A to $190.0 million in Q2 2025 from the same period last year, while for Sep 2025 it was $190.0 million, marking a year-over-year decrease of 9556.07%. This contributed to the annual value of $4.2 billion for FY2024, which is 830000.0% up from last year.
  • As of Q2 2025, Gilead Sciences' Asset Writedowns and Impairment stood at $190.0 million.
  • Gilead Sciences' 5-year Asset Writedowns and Impairment high stood at $2.7 billion for Q1 2022, and its period low was $50.0 million during Q4 2023.
  • Its 4-year average for Asset Writedowns and Impairment is $1.4 billion, with a median of $1.8 billion in 2024.